Pages that link to "Item:Q7978"

← Introduction (Q7978)

What links here

Page:  Namespace:  all (Main) Talk User User talk Wikibase.slis.ua.edu Wikibase.slis.ua.edu talk File File talk MediaWiki MediaWiki talk Template Template talk Help Help talk Category Category talk Item Item talk Property Property talk Module Module talk   Invert selection

Filters

Hide transclusions | Hide links | Hide redirects

The following pages link to Introduction (Q7978):

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

• Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x) (Q10752) ‎ (← links)
• Section 3: COVID-19: Neuro-invasive potential of SARS-nCoV-2 as cause of delirium (from DOI: 10.1186/s13054-020-02882-x) (Q10753) ‎ (← links)
• Section 4: COVID-19: ICU delirium management:potential problems and solutions (from DOI: 10.1186/s13054-020-02882-x) (Q10754) ‎ (← links)
• Section 1: Introduction (from DOI:10.14218/ERHM.2020.00023) (Q10798) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2) (Q10986) ‎ (← links)
• Section 2: SARS-CoV-2 Biology and Clinical Implications (from DOI: 10.1007/s11886-020-01293-2) (Q10987) ‎ (← links)
• Section 3: Cardiovascular Comorbidities and COVID-19 Outcomes (from DOI: 10.1007/s11886-020-01293-2) (Q10988) ‎ (← links)
• Section 3.1: Cardiac Complications of COVID-19 (from DOI: 10.1007/s11886-020-01293-2) (Q10989) ‎ (← links)
• Section 3.1.1: Myocardial Injury and Heart Failure (from DOI: 10.1007/s11886-020-01293-2) (Q10990) ‎ (← links)
• Section 3.1.2: Arrhythmia (from DOI: 10.1007/s11886-020-01293-2) (Q10991) ‎ (← links)
• Section 1: Introduction (from DOI: 10.3201/eid2605.200146) (Q11165) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1016/j.adro.2020.04.015) (Q11167) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1084/jem.20200653) (Q11178) ‎ (← links)
• Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653) (Q11179) ‎ (← links)
• Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653) (Q11180) ‎ (← links)
• Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653) (Q11181) ‎ (← links)
• References (from DOI: 10.1084/jem.20200653) (Q11182) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1016/j.clim.2020.108427) (Q11187) ‎ (← links)
• Section 2: Epidemiological data of COVID-19 (from DOI: 10.1016/j.clim.2020.108427) (Q11188) ‎ (← links)
• Section 3: Mechanism of SARS-CoV-2 invasion into host cells (from DOI: 10.1016/j.clim.2020.108427) (Q11189) ‎ (← links)
• Section 4: Host response to SARS-CoV-2 (from DOI: 10.1016/j.clim.2020.108427) (Q11190) ‎ (← links)
• Section 5: Potential explanation for the difference between children and adults in COVID-19 (from DOI: 10.1016/j.clim.2020.108427) (Q11191) ‎ (← links)
• Section 6: Conclusions (from DOI: 10.1016/j.clim.2020.108427) (Q11192) ‎ (← links)
• Financial support (from DOI: 10.1016/j.clim.2020.108427) (Q11193) ‎ (← links)
• Declaration of Competing Interest (from DOI: 10.1016/j.clim.2020.108427) (Q11194) ‎ (← links)
• References (from DOI: 10.1016/j.clim.2020.108427) (Q11195) ‎ (← links)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)